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Aibek E MirrakhimovAbstract
Chronic obstructive pulmonary disease, metabolic syndrome and diabetes mellitus are common and
underdiagnosed medical conditions. It was predicted that chronic obstructive pulmonary disease will be the third
leading cause of death worldwide by 2020. The healthcare burden of this disease is even greater if we consider the
significant impact of chronic obstructive pulmonary disease on the cardiovascular morbidity and mortality.
Chronic obstructive pulmonary disease may be considered as a novel risk factor for new onset type 2 diabetes
mellitus via multiple pathophysiological alterations such as: inflammation and oxidative stress, insulin resistance,
weight gain and alterations in metabolism of adipokines.
On the other hand, diabetes may act as an independent factor, negatively affecting pulmonary structure and
function. Diabetes is associated with an increased risk of pulmonary infections, disease exacerbations and worsened
COPD outcomes. On the top of that, coexistent OSA may increase the risk for type 2 DM in some individuals.
The current scientific data necessitate a greater outlook on chronic obstructive pulmonary disease and chronic
obstructive pulmonary disease may be viewed as a risk factor for the new onset type 2 diabetes mellitus.
Conversely, both types of diabetes mellitus should be viewed as strong contributing factors for the development of
obstructive lung disease. Such approach can potentially improve the outcomes and medical control for both
conditions, and, thus, decrease the healthcare burden of these major medical problems.
Keywords: COPD, Dysglycemia, Insulin resistance, Obesity, Metabolic syndrome, Diabetes mellitus endothelial
dysfunction, VasculopathyIntroduction
Chronic obstructive pulmonary disease (COPD) defines a
group of chronic inflammatory pulmonary disorders
characterized by partially reversible airflow limitation [1].
The notion that COPD is primarily a lung disease has
been challenged, and the broader definition of COPD as
a systemic inflammatory syndrome has been proposed
[2]. Evidence for this approach has been provided by
strong associations with increased rates of cardiovascular
diseases [3], anemia [4], musculoskeletal disease [5,6] and
malignant conditions seen in COPD patients [7,8].
Moreover, it is predicted that COPD will be the third
leading cause of death worldwide by 2020, which will
impose an even greater burden on the healthcare system
globally [9]. If the mortality from comorbid conditions
associated with COPD is taken into count, then thisCorrespondence: amirrakhimov1@gmail.com
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reproduction in any medium, provided the ordisease poses an even greater impact on health out-
comes. The common risk factors for COPD are air pol-
lution, aging, respiratory infections, bronchial asthma
(BA), low socioeconomic status [1].The COPD grading
is presented in Table 1.
Type 2 diabetes mellitus (DM) and metabolic syn-
drome (MetS) are particularly common medical disor-
ders and are leading causes of morbidity and mortality
worldwide. Disturbances in glucose metabolism are more
common in COPD patients than in COPD free indivi-
duals. COPD, MetS and type 2 DM are associated with
advanced age, which may in part explain this observation.
It is well known that offspring of affected parents are
more likely to develop both COPD and type 2 DM.
Smoking during pregnancy can in part explain the associ-
ation between COPD and type 2 DM, due to delivery of
low birth weight infants, which is a known risk factor for
both diseases [10]. In addition, smoking can contribute
to the occurrence of these diseases via its effects onLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Global Initiative for Chronic Obstructive Lung
Disease (GOLD) Grading system for COPD (Adapted from
reference #) [1]
Grade Severity Spirometry findings
GOLD 1 Mild FEV1/FVC<0.7 and FEV1≥80% predicted
GOLD 2 Moderate FEV1/FVC<0.7 and 50%≤FEV1≥80%
predicted
GOLD 3 Severe FEV1/FVC<0.7 and 30%≤FEV1≥50%
predicted
GOLD 4 Very Severe FEV1/FVC<0.7 and FEV1>30% predicted
Abbreviations: GOLD: Global Initiative for Chronic Obstructive Lung Disease;
FEV1: Forced Expiratory Flow in 1 second; FVC: Forced Vital Capacity.
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ever, the pathogenesis of glucose metabolism dysregula-
tion is likely to be much more complex, whereby myriads
of pathways are likely to be implicated, and much is still
to be discovered and clarified.
On the other hand, type 1 DM and other forms of DM
are much less common than type 2 DM [13], in part due
to the growing burden of obesity and its associations
with type 2 DM [14]. The risk factors for type 1 DM are
not well understood and are of minor relevance to this
manuscript. The major risk factors for type 2 DM are
obesity, sedentary lifestyle, family history/genetic predis-
position, aging, MetS, gestational diabetes and smoking.
Epidemiological data suggest that certain comorbid
diseases, including DM are much more common in
patients with COPD than in controls [3,15], and are
associated with a worse COPD outcome [16]. As shown
by Cazzola et al., patients with COPD have a higher
burden of type 2 DM [17]. Sode et al. showed that
patients with COPD have a greater burden of not only
DM, but also of myocardial infarction, lung cancer,
depression and hip fracture [18]. In contrast to these
findings, Korean researchers did not find any association
between COPD and greater DM prevalence, which may
be related to high percentage of underweight subjects in
the studied population [19].
The goal of this article is to summarize the published
data on COPD and dysglycemic states. Firstly, the back-
ground of the problem and possible pathophysiological
mechanisms will be discussed. Secondly, the article will
focus on the clinical data and epidemiology of type 2 DM
in COPD and the impact of both conditions on the clinical
course of each other. Thirdly, we will briefly discuss the
data on overlap syndrome, coexistence of obstructive
sleep apnea (OSA) and COPD on the risk of type 2 DM.
Pathophysiology of glucose metabolism disturbances
in COPD
Weight as a risk factor for COPD
Obesity is a growing health concern worldwide, primarily
due to modern lifestyle changes and sedentarism. Obesityis one of the major criteria of MetS and a well established
risk factor for new onset type 2 DM [20].
Obesity is known to affect pulmonary function and
lung volumes. Obesity is associated with a decrease in
expiratory reserve volume (ERV) and functional residual
capacity (FRC), due to its extrapulmonary restrictive
component [21]. Aside from this, obesity can perpetuate
both systemic and pulmonary inflammation, since exces-
sive adipose tissue is able to produce various proinflam-
matory cytokines including interleukin-6 (IL-6) and
tumor necrosis factor alpha (TNF-α). On the other hand,
excessive central adiposity is associated with a decrease
in adiponectin levels, which is known for its anti-
inflammatory properties, and this can contribute to the
pulmonary and vascular damage [22].
Leone et al. studied the association between the com-
ponents of MetS and airflow obstruction in 129,965 men
[23]. MetS was associated with low forced expiratory
volume in one second (FEV1) (odds ratio (OR) 1.28; 95%
confidence interval (CI) 1.20-1.37) and forced vital cap-
acity (FVC) (OR 1.41; 95% CI 1.31-1.51), independently
from possible confounding factors. Abdominal obesity
was strongly associated with low FEV1 (OR 1.94; 95% CI
1.80-2.09) and FVC (OR 2.11; 95% CI 1.95-2.29). It is
particularly pertinent to note that hyperglycemia, high
blood pressure and dyslipidemia were related to airflow
obstruction. This finding indirectly supports a potential
impact of MetS and type 2 DM on the pathogenesis and
clinical course of COPD.
Similar results were obtained in a study by Lam et al.,
who enrolled 7,358 adults [24]. These researchers
showed that abdominal obesity was associated with air-
flow obstruction independently from smoking (OR 1.43;
95% CI 1.09-1.88). However, a study performed by Paek
et al., who enrolled 4,001 individuals failed to document
any relationship between MetS and airflow limitation [25].
Marquis et al. enrolled 38 subjects with COPD and 34
controls to test whether MetS and its components were
more common in COPD patients [26]. Overall 47% of
COPD patients had three or more MetS components in
comparison with 21% of control subjects, and the preva-
lence of obesity was approximately two times higher in
the COPD group.
Steuten et al. recruited 317 subjects with COPD to
study the prevalence of weight distribution in COPD
patients in a Dutch primary care setting [27]. Obesity
was much more prevalent in mild to moderate COPD
(16-24%) disease than in severe disease (6%) in this
study.
A research group from the University of California
in San Francisco enrolled 355 patients with COPD to
study the impact of body composition on functional
status in patients with various stages of COPD [28].
Obesity (BMI≥30 kg/m2) was diagnosed among 54% of
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general US population.
Guerra et al. in a nested case control study tested
whether BMI was associated with emphysema and bron-
chitis phenotypes of COPD [29]. In subjects with bron-
chitis, 25% of COPD cases had a BMI≥28kg/m2 compared
with 16% of controls. Moreover, a BMI≥ 28kg/m2 was
associated with an increased risk of being diagnosed
with bronchitis (OR 1.80; 95% CI 1.32-2.46), whereas,
the presence of emphysema was related to decreased
weight.
However, some previously published data suggests
that low BMI is a risk factor for COPD [30] and
others have reported that obese men have a lower annual
FEV1 decline [31].
It is well known, that a low BMI in patients with
COPD is considered to be a risk factor for all cause
related and pulmonary related mortality [32]. This was
first demonstrated by Celli et al., who validated a globally
used prognostic tool, more known as the BODE Index.
Others have validated three item questionnaire for a poor
COPD related quality of life, with a low BMI being one
of the criteria [33]. However, it is worth emphasizing that
a decrease in BMI seen in advanced COPD is likely to be
explained by a loss of fat free mass, such as skeletal
muscle [34]. Skeletal muscle loss in advanced COPD may
further contribute to the deterioration in the clinical
course of the disease, which is pathophysiologically simi-
lar to cancer cachexia.
Landbo et al. recruited 1,218 men and 914 women
with FEV1/FVC<0.7 and prospectively studied the impact
of nutritional status on mortality in COPD from all
causes [35]. Importantly, smoking status, spirometry
data, BMI and respiratory symptoms were assessed at
baseline and after 17 years. After adjustment for possible
confounders, a lower BMI was associated with greater
mortality compared with a normal or high BMI (relative
risk (RR) 1.64; 95% CI 1.20-2.23); this association was
strongest in patients with COPD.
The same research group tested whether a change in
BMI was associated with mortality in a cohort of
patients with COPD and controls [36]. Interestingly, a
loss of > three BMI units was associated with increased
all-cause mortality in controls (RR 1.63; 95% CI 1.38-1.92)
as well in COPD patients (RR 1.71; 95% CI 1.32-2.23).
Weight loss was related to an increased risk of COPD
related mortality (RR 2.14; 95% CI 1.18-3.89), whereas
weight gain was associated with increased mortality only
in controls.
Jee et al. studied 1,213,829 Koreans to prospectively
study the impact of weight on mortality in patients with
COPD [37]. These researchers found that a lower BMI
was associated with increased mortality from respiratory
causes, whereas a relationship was observed betweenhigh BMI and increased mortality from cardiovascular
diseases or malignancies.
These data highlight the unresolved issue of the
“obesity paradox” seen in many chronic diseases, such
as COPD and heart failure (HF), where a higher BMI
is associated with a decrease in overall mortality. The
discrepancies among COPD studies are likely because
of different phenotypes of disease being enrolled, such
as emphysema predominant and bronchitis predominant.
Indeed, emphysema predominant phenotype is associated
with a loss of skeletal muscle, rather than a loss of body
fat, which may explain differences in mortality in patients
with normal and low BMI. Thus, future studies are
needed to address the fat free mass rather than BMI in
studying the impact body weight on morbidity and mor-
tality in patients with COPD. Indeed, loss of a skeletal
muscle may explain a greater pulmonary function decline
in patients with low BMI compared to patients with nor-
mal BMI as was shown by Watson et al. [31].
Adipokines and COPD
Adipose tissue is an active endocrine organ producing
various substances, which regulate biological processes
including glucose and insulin metabolism. Leptin and
adiponectin are the most studied adipokines to date.
Leptin may decrease the expression of insulin as well as
decrease glucose uptake by pancreatic β cells. Adiponec-
tin, on the other hand, may upregulate insulin secretion
when it is physiologically required. The reader is referred
to some comprehensive review articles on the topic of
adipokines and glucose metabolism [38,39]. A summary
of the adipokines and their relationship to DM and
COPD is presented in Table 2.
Overall there is a paucity of published data on COPD
and adipokines. Some of the published reports suffer
from flaws in assessing the effects of adipokines on lung
function and on the course of COPD. Nevertheless, the
current data on this topic will be briefly reviewed.
Broekhuizen et al. enrolled 14 patients with moderate
COPD to study the relationship between sputum leptin
and other inflammatory markers [40]. Sputum leptin
levels were related to sputum C-reactive protein (CRP)
(p<0.001) and TNF-α (p< 0.01).
Bruno et al. recruited 15 smokers without COPD and
27 smokers with mild to moderate COPD to study the
pulmonary expression of leptin and its receptor [41].
They found that patients with COPD had increased pul-
monary leptin expression, which is associated with air-
flow inflammation and obstruction.
A research group from Maastricht University, in the
Netherlands enrolled 15 male subjects with bronchitis
predominant COPD and 27 male subjects with emphy-
sema predominant disease to study the association be-
tween systemic inflammation, leptin and energy balance
Table 2 Key proinflammatory cytokines and adipokines and their potential role in COPD and DM (Adapted from
references #) [38-77]
Name Major origin Physiological function Data on COPD Data on DM
CRP Liver/Hepatocyte Proinflammatory. COPD is independently
associated with increased
levels of CRP. Moreover,
CRP may predict the
future onset of COPD.
Elevated CRP levels may predict











May be a risk factor for the







IL-1 is implicated in the
pathogenesis of COPD
related inflammation.
An increase in IL-1β may predict







of the synthesis of CRP and
other proinflammatory




IL-6 was shown to increase
the risk for the new onset
type 2 DM.





No data on fibrinogen and the
risk of new onset type 2 DM.
Leptin Adipocyte Appetite regulation. Possible
proinflammatory actions.
Leptin levels are increased
in patients with COPD.
May contribute to COPD
related weight loss and
pulmonary function decline.
Leptin may increase the risk of
type 2 DM. Leptin may
participate in the development
of DM related complications
via its proinflammatory actions.




Adiponectin levels are increased
in patients with COPD




Adiponectin may prevent the
development of type 2 DM
via its anti-inflammatory and
proinsulin actions.
Resistin Leukocytes Proinflammatory and insulin
antagonizing actions.
Resistin levels may be increased
in COPD and mediate IR.
Resistin may directly participate
in the development of IR.
Abbreviations: CRP: C-Reactive Protein; DM: Diabetes Mellitus; IL: Interleukin; TNF-α: Tumor Necrosis Factor alpha.
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tin concentration, most likely due to lower body weight
(p= 0.02). A positive correlation between serum leptin
and soluble TNF-α receptor levels was observed in
patients with emphysema.
Opposing results were obtained by Takabatake et al.,
who recruited 31 people with COPD and 15 controls
[43]. The mean BMI in COPD patients was significantly
lower than in controls (BMI = 18.1 +/− 2.7 kg/m2 versus
22.8 +/− 2.2 kg/m2 respectively; p< 0.0001), which may
explain the lower leptin levels seen in COPD patients
(p < 0.05). These investigators failed to find any associ-
ation between leptin levels and inflammatory biomarkers.
Karakas et al. enrolled 30 subjects with COPD and 20
healthy controls to assess the possible association be-
tween serum leptin levels and body composition [44].
Patients were grouped based on their BMI and serum
leptin concentration. These researchers found an inverse
relationship between serum leptin levels and BMI.
Wang et al. enrolled 57 patients with stable COPD
and 31 controls to study the association between nutri-
tional status and both leptin and resistin levels [45].Leptin levels were positively correlated with resistin
levels and both were associated with lower BMI. In sup-
port of this notion, a study performed by Al Mutairi
et al., who studied the association between circulating
resistin and inflammation showed a direct association
between resistin levels and inflammatory obstructive
airway disease [46]. These researchers speculated that
resistin may be a novel disease marker and play a role
in the development of insulin resistance (IR) in COPD.
Hansel et al. enrolled 429 subjects to study the rela-
tionship between leptin receptors and the rate of pul-
monary function decline in patients with COPD [47].
They identified 21 single nucleotide polymorphisms
(SNP) of the leptin receptor gene which were signifi-
cantly associated with accelerated loss of lung function.
This study provided information that certain leptin re-
ceptor gene polymorphisms may act as predisposing
factors for COPD incidence among smokers, which could
explain why not all smokers develop obstructive airway
disease.
Calikoglu et al. recruited 26 patients with stable
COPD, 16 patients with COPD exacerbation and 15
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and nutritional parameters [48]. These investigators
found that leptin levels were lower in patients with stable
COPD in comparison with controls; however, TNF-α was
higher in stable COPD than in controls and COPD ex-
acerbation was associated with an increase in serum
leptin and TNF-α. Dutch researchers found similar
results with higher leptin levels during COPD exacerba-
tion. It was speculated that this phenomenon could be
explained by systemic inflammation and/or through
high dose systemic corticosteroid treatment [49]. It was
proposed that leptin may participate in the pathogenesis
of pulmonary cachexia through its anorexigenic and
metabolic effects [42].
Pan et al. enrolled 56 patients experiencing COPD ex-
acerbation to study the association between dysglycemia,
IR and in hospital clinical course [50]. The authors con-
cluded that leptin induced IR and hyperglycemia pro-
longed hospital stay and adversely affected pulmonary
function. Kythreotis et al. found that leptin levels were
elevated during exacerbation and 2 weeks after the dis-
charge [51].
However, an association between leptin and TNF-α
was not found in a study performed by Yang et al. [52].
Small sample size and the population studied may
underlie the lack of association in this work compared
to other studies.
Tomoda et al. recruited 31 patients with COPD and
12 controls to study the role of adiponectin in patients
with COPD [53]. Plasma adiponectin was higher among
patients with COPD and correlated with residual volume
(RV) (p<0.05), TNF-α (p<0.05) and was inversely corre-
lated with BMI (p<0.01). These researchers speculated
that high adiponectin levels may explain why COPD
patients with a low BMI have decreased mortality due to
cardiovascular causes.
Kirdar et al. enrolled 36 patients with COPD exacerba-
tion and 17 controls to assess the role of adiponectin as
a potential COPD biomarker [54]. Serum levels of adipo-
nectin were higher among COPD patients (p<0.001);
however, leptin metabolism was not altered in COPD
exacerbation.
Miller et al. reported that patients with emphysema
had a higher expression of pulmonary adiponectin
[55], whereas Summer et al. showed that mice lacking
adiponectin were prone to emphysema development
[56].
Yoon et al. measured adiponectin levels in patients en-
rolled in the Lung Health Study to investigate the rela-
tionship between this adipokine and COPD [57]. These
researchers found that increased adiponectin was related
to a decrease in cardiovascular mortality, but was asso-
ciated with an increase in mortality due to respiratory
causes.Breyer et al. studied the various adipokines and
their expression in patients with COPD [58]. These
researchers showed that patients with COPD had higher
levels of CRP, IL-6, fibrinogen and adiponectin. Gender
specific analysis demonstrated, that males with COPD
had higher CRP, IL6 and fibrinogen levels, whereas,
females with COPD had higher levels of CRP and fibrino-
gen only. Moreover, in female patients with COPD, leptin
was correlated with CRP and fibrinogen, but this correl-
ation was not observed in males with COPD. A negative
correlation was shown between adiponectin and CRP in
patients with COPD.
Based on the current data, leptin may propagate both
pulmonary and systemic inflammation and together with
resisitin contribute to the pathogenesis of related dysgly-
cemia. Data on the adiponectin and mortality is quite
intriguing and conflicting, which merits further research
to explore potential mechanisms. In a mouse model of
emphysema, it was shown that adiponectin may protect
against the emphysema development. Thus, more studies
are needed on the role of adipokines in the development
and course of COPD, and whether they are not simply
the markers of COPD progression.
COPD, systemic inflammation and oxidative stress
As in many other chronic medical conditions, COPD is
associated with low grade systemic inflammation. Various
factors can contribute to this finding such as the spill of
inflammatory mediators from the pulmonary system into
the circulation, hypoxia, effects of obesity and hormonal
disturbances. Current evidence suggests that excessive
oxidative stress can be a risk factor for new onset type 2
DM and conversely, oxidative stress may be a conse-
quence of new onset type 2 DM [59]. COPD as well as
other pathologies, in which hypoxia is a feature is asso-
ciated with an excessive oxidative state [60]. The reader is
referred to a comprehensive review of hypoxia and metab-
olism for a more detailed discussion of this topic [61]. A
summary of some of the key proinflammatory mediators
and their relationship with DM and COPD is presented in
Table 2. A simplified interrelationship between inflamma-
tion and oxidative stress is presented in Figure 1.
It is believed that inflammation increases the risk of
future type 2 DM. Pradhan et al. studied 27,628 females
to assess the impact of inflammatory biomarkers on the
new onset type 2 DM [62]. They group found that the
highest quartile of IL-6 and CRP gave a RR of 2.3 (95%
CI 0.9-5.6) and 4.4 (95% CI 1.5-12.0) respectively.
Spranger et al., studied 27,548 individuals to assess the
relationship between inflammation and new onset type 2
DM [63]. These researchers found that interleukin-1beta
(IL-1β) and IL-6 may be useful predictors of the develop-
ment of new onset type 2 DM.
Figure 1 A simplified interrelationship between inflammation
and oxidative stress.
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and Hu et al. [65] showed a positive association between
TNF-α and the development of IR and overt type 2 DM.
Similar data came from the Atherosclerosis in Com-
munities Study, which showed that low grade systemic
inflammation predicts the incident type 2 DM [66].
Botelho et al. demonstrated that interleukin-1alpha
(IL-1α) plays a major role in the development of neutro-
philia in smoke induced inflammation in a mouse
model [67].
Altaran et al. enrolled 50 patients with COPD to study
the association between IL-6 and COPD severity [68].
These researchers showed an increase in IL-6 among
patients with COPD and a possible independent contri-
bution of IL-6 to airflow limitation. However, the results
of the study cannot be generalized, since the majority of
study participants had a history of sulfa mustard expos-
ure. He et al. showed that a SNP in the IL-6 gene174G/
C was associated with a rapid decline in FEV1 and
COPD susceptibility among smokers [69]. Van Durme
et al. showed that an increase in IL-6 was associated
with an increased risk of COPD development; however,
no association was found between polymorphisms in the
IL-6 gene and such risk [70]. Data from further study,
performed by Yanbaeva et al. supported the hypothesis
of an increased risk of future COPD development
associated with high IL-6, particularly for the IL-6 H2
haplotype [71]. Tkacova et al. studied the adipose tis-
sue expression of CD40, a key receptor for the TNF in
20 patients with COPD [72]. These researchers showed
that patients with severe COPD had a higher expres-
sion of CD40, which was inversely related to a lower
partial pressure of oxygen. Thus, COPD related adi-
pose tissue dysfunction may further enhance systemic
inflammation and IR.
According to a meta-analysis performed by Gan et al.,
patients with COPD have higher levels of circulating
neutrophils, CRP, fibrinogen and TNF-α. [73]. Vozarova
et al., showed that a higher white blood cell count wasassociated with an increased risk of type 2 DM develop-
ment [74]. Aside from this, elevated CRP has been
shown to predict hospitalization and death in COPD
[75], and CRP levels in COPD have a strong genetic
background [76]. Moreover, a high CRP levels may act
as a risk factor for future development of COPD among
smokers [71,77]. The fact that only a small number of
smokers develop COPD may be based on genetic altera-
tions of common proinflammatory cytokines such as
CRP and IL-6.
Indeed, the genetically mediated proinflammatory state
in some individuals with COPD may underlie the clinical
phenotype of patients with frequent COPD exacerba-
tions. All of the findings may help in our understanding
of the increase in cardiovascular morbidity and mortal-
ity, as well as the increased metabolic risk seen in
COPD.
Both DM and COPD are associated with systemic in-
flammation and, on the other hand, systemic inflamma-
tion is associated with the disease risk, leading to a
vicious cycle. Indeed, it was shown that certain genetic
polymorphisms of common pro- inflammatory mole-
cules may increase the risk for COPD in smokers.
Hypoxia and glucose metabolism
Pallayova et al. hypothesized that pancreatic β cells may
be damaged by hypoxia, but the focus of their study was
primarily on obstructive sleep apnea, which is associated
with intermittent hypoxia, rather than chronic hypoxia
seen in COPD [78]. However, both of these diseases
may share some pathophysiological pathways, which
may be mediated by the hypoxia inducible factor family
(HIF) [61].
Based on the available data it is likely that different
tissues have various metabolic responses to hypoxia.
Interestingly, skeletal muscles under hypoxia have a
higher glucose uptake [79], and increased sensitivity of
skeletal muscles to insulin during exercise [80]. However,
patients with COPD receiving oxygen therapy have less
muscular IR [81]. This may be explained by the fact that
long standing hypoxia may detrimentally affect skeletal
muscle insulin sensitivity compared with acute muscular
hypoxia seen in exercise.
HIF-1α expression is increased in hypoxic pancreatic
β cell regions, undergoing programmed cell death, which
may simply indicate an effect of hypoxia on the expres-
sion of HIF-1α, with the latter having no role in the
pathogenesis of apoptosis. Alternatively HIF-1α may
exert unique effects on the β cells [82]. Cheng et al.
showed that HIF-1α has significant and beneficial effects
on pancreatic β cell function, and hypothesized that
HIF-1α may be a novel target to improve the function
of insulin producing cells [83].
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by Oltmanns et al., which exposed healthy volunteers to
hypoxia under euglycemic clamp [84]. These researchers
found that hypoxia caused glucose intolerance, and this
phenomenon could be partly explained by an increase
in epinephrine release.
The effects of hypoxia on the function of adipocytes
seem to be straightforward. Chen et al. showed that
hypoxia decreased the production of adiponectin and
increased the production of plasminogen activator
inhibitor-1 which may contribute to a greater cardio-
metabolic risk [85].
Aside from this, a hypoxia mediated increase in
HIF-1α can induce adipose tissue fibrosis and resistance
to insulin [86,87].
On the other hand, hyperglycemia is able to down-
regulate HIF-1α, and via this mechanism contributes
to the pathophysiology of angiopathic conditions com-
monly seen in patients with DM [88].
Based on above findings, it is likely that hypoxia can
mediate its detrimental effects on glucose metabolism
and IR at least through the effects on insulin sensitivity
at the level of adipose tissue and skeletal muscle.
Muscle metabolic pathways in COPD
IR at the level of skeletal muscle plays a role in the
pathogenesis of type 2 DM. Earlier reports linked this
phenomenon to a decreased amount of mitochondria in
diabetic skeletal muscle, but new data suggest a
decreased functional status of this cellular organelle [89].
From a theoretical point of view, it is plausible that
COPD and associated hypoxia, can detrimentally affect
mitochondria. However, it should be noted, that the evi-
dence regarding the role of hypoxia in decreased glucose
transport in skeletal muscle is controversial [90]. The in-
formation on this topic is relatively scant and will be
briefly discussed below.
Wuyam et al. showed that patients with COPD had
decreased aerobic capacity compared to healthy controls
[91]. However, in contrast to their findings, others
explained this association by a decreased level of physical
activity at baseline, and a shift in type of muscle fiber,
and, they, therefore, doubted the existence of an intrinsic
mitochondrial problem in COPD [92].
Jakobsson et al. group reported that patients with
advanced COPD had upregulated glycolysis in quadriceps
femoris muscles, but lower muscular aerobic capacity
[93]. This finding points toward the existence of an adap-
tation of skeletal muscle to hypoxia, by upregulating glu-
cose carriers, such as GLUT-4.
COPD patients experience a shift in the skeletal
muscle fiber [94], which may explain a decrease in oxida-
tive capacity [91,95]; such a fiber shift has been shown to
be associated with a greater COPD severity [96]. Patientswith COPD have impaired β oxidation of fatty acids,
electron transport chain and citric acid cycle, all of which
are known to take place in mitochondria [97].
A key study performed by Green et al. showed that
muscles from patients with COPD had lower levels of
glucose transporter-4 (GLUT-4) compared with controls,
which is known to be closely linked to insulin action
[98]. However, as mentioned previously, others have
failed to show any detrimental effects of hypoxia on glu-
cose uptake by skeletal muscle cells.
Moreover, IR may synergistically impair muscle func-
tion, since it is associated with decreased muscle
strength, even in patients without overt DM [99].
It is theoretically plausible, that longstanding hypoxia
have different molecular effects on skeletal muscle me-
tabolism compared with muscle hypoxia induced by
physical exercise in subjects without pulmonary disease.
However, this conclusion is not based on firm evidence
and further research is needed to clarify the effects of
hypoxia and COPD on glucose metabolism in skeletal
muscle.
COPD and hormonal dysregulation
From a theoretical viewpoint the alterations in insulin
opposing hormones can explain the association between
the development of COPD and dysglycemia. However, it
should be noted that the evidence is scant and contro-
versial. Nevertheless, we will briefly discuss the data on
COPD and hormones, which are associated with MetS
and type 2 DM.
There are some reports linking abnormalities in andro-
gen metabolism with the development of type 2 DM
[100]. The exact mechanisms of these associations are
not clear, but they may be related to the beneficial effects
of testosterone on weight, insulin sensitivity and modula-
tion of inflammation. Svartberg et al. showed that men
with lower levels of free and total testosterone had lower
numbers of FEV1 and FVC, independently from potential
confounders [101].
Laghi et al. enrolled 101 patients with COPD and mea-
sured both free and total testosterone [102]. These
researchers found that approximately 40% of patients
with COPD were hypogonadal; however, they did not
find any association between testosterone levels and
pulmonary function. Notably, the prevalence of hypo-
gonadism in patients with COPD has been shown to be
greater than in an age-matched population without this
disease [103], and the lack of association between andro-
gens and pulmonary function could be explained by the
small sample size and lack of a control group in this
study.
In contrast to the study performed by Laghi et al.
[102], Van Vliet et al. showed that hypogonadism was
associated with decreased physical endurance, muscle
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with COPD [104]. It is difficult to prove causality be-
tween low testosterone and COPD, since multiple
mechanisms are likely to act simultaneously. However,
it is possible that hypoxia may underlie the develop-
ment of hypogonadism in patients with pulmonary
disease [105].
Catecholamine hormones are known to be insulin
antagonists and contribute to the occurrence of hyper-
glycemia [106]. Kanstrup et al. showed an association
between prolonged hypoxia and the development of
enhanced catecholamine output in eight healthy men
[107]. In another study, Scalvini et al. showed that
patients with COPD had higher catecholamine levels
which were independently related to a decrease in FEV1
[108]. Bratel et al. showed that patients with severe noc-
turnal hypoxemia treated with long term oxygen therapy
experienced a reduction in nocturnal norepinephrine,
suggesting a potential causal role of hypoxia in the over-
activation of the sympathetic nervous system in patients
with COPD [109].
Abnormalities in the renin angiotensin aldosterone
system (RAAS) are implicated in the development and
pathogenesis of cardiovascular diseases, MetS and type 2
DM [110]. Farber et al., in two published studies,
showed that patients with COPD had higher levels of al-
dosterone and an increase in plasma renin activity
[111,112]. Stewart et al. found that patients with COPD
had increased levels of vasopressin and aldosterone,
which could be explained by COPD, related autonomic
neuropathy [113]. Alternatively, the RAAS activity in
patients with COPD can be upregulated by increased
sympathetic tone, hypoxia and underlying comorbid
states such as cardiac and renal pathologies. The import-
ance of RAAS overactivation was highlighted by Mancini
et al., who showed that drugs targeting the RAAS may
improve survival in patients with COPD [114].
Vitamin D is implicated into the pathogenesis of
myriad of extraskeletal diseases including both major
types of DM [115,116]. This relationship can be
explained by the anti-inflammatory and antioxidant
effects of vitamin D as well as through its modulation of
the RAAS activity. Moreover, patients with COPD ex-
hibit a trend towards lower levels of vitamin D [117].
However, it is difficult to conclude causality, since
patients with COPD may have a lower level of activity
and, thus, have less sun exposure.
Evidence for an association between COPD and thy-
roid function is scant and predominantly negative [118].
To summarize, COPD is associated with abnormalities
in metabolism of androgen hormones, vitamin D, cate-
cholamines and RAAS. However, more studies are
needed to clarify the role of these hormonal systems in
the pathogenesis of COPD related IR.Clinical data on COPD and the risk of DM/MetS
COPD, reduced lung function and the risk of new onset
type 2 DM
Reduced lung function and the risk of type 2 DM
Lazarus et al. in a prospective observational study
showed that baseline values of FVC, FEV1 and max-
imal mid-expiratory flow rate (MMEF) are negatively
associated with IR even after adjustment for potential
confounders [119].
Ford et al. showed that FEV1 and FVC values at
baseline were inversely associated with the incidence
of type 2 DM [120]. It is important to note that re-
strictive, but not obstructive lung disease was asso-
ciated with the incidence of new onset type 2 DM.
Similar findings were shown by Paek et al. and Wan-
namethee et al. [25,121], who demonstrated that re-
strictive lung diseases were strongly associated with
new type 2 DM. These results were statistically sig-
nificant even after adjustment for confounding fac-
tors such as age, gender and weight.
Researchers from the Johns Hopkins University studied
11,479 subjects free of type 2 DM and followed them for
nine years [122]. They found that lower FVC was inde-
pendently associated with new onset type 2 DM in
both men and women, independently from potential
confounders such as age, weight and race. Hsiao
et al. showed that reduced baseline FVC and FEV1
were independently related to a greater risk of future
development of MetS [123]. A shared pathophysiology
may underlie this association or alternatively, reduced
lung volumes may simply be the markers of lower phys-
ical endurance in patients at risk for the development of
MetS.
Similar data have been reported by Engstrom et al.,
who showed that reduced pulmonary function was in-
versely associated with the development of type 2 DM
[124]. In a later study, Engstrom et al. showed that low
FVC was associated with an increased risk of IR and the
development of new onset type 2 DM [125].
In a recent cross-sectional study, Kwon et al. showed
that reduced FEV1 and FVC are directly related to the
new onset type 2 DM [126]. The results stayed signifi-
cant even after adjustment for age, weight, health
literacy and exercise.
Cross-sectional studies performed in Japanese [127]
and Korean men [128,129] showed an association be-
tween reduced FVC and an increased risk of both MetS
and type 2 DM.
However, the association between type 2 DM and
reduced lung function should be interpreted with caution.
It is well known that most of the participants enrolled in
these studies were obese, and obesity is associated with
reduced respiratory muscle performance, which could
underlie this relationship [130,131].
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monary disease to study the impact of decreased lung
function on the incidence of type 2 DM [132]. They
showed that reduced pulmonary function was associated
with increased incidence of type 2 DM independently
from BMI, smoking status and baseline glycated
hemoglobin (hazard ratio (HR) 13; 95% CI, 1.01-1.26).
Thus, the observed association could be explained by
three possibilities: reduced lung performance and inci-
dence of type 2 DM share similar pathophysiological
pathways (such as low grade inflammation); secondly,
that reduced lung performance could be just a marker of
reduced physical endurance; thirdly, that reduced lung
function may simply portray the overall health status of
individuals prone to develop type 2 DM, with obesity
being the most important confounding factor.Table 3 Key studies on pulmonary volumes and the risk of ne
First author and year Country Study design Popula
Lazarus et al.
[119]; 1998
USA Prospective cohort study







Sweden Prospective cohort study









Sweden Population based cohort
study with a mean
follow up of 13.9 years















Kwon et al. [126];
2012
Korea Prospective cohort study









Heianza et al. [132];
2012
Japan Observational study with
a 4 year follow up
n: 5,346
48.6 y
Abbreviations: BMI: Body Mass Index; CI: Confidence Interval; FEV1: Forced Expirat
Maximal Mid-Expiratory Flow; OR: Odds Ratio; VC: Vital Capacity.A summary of the key studies on the topic of reduced
pulmonary function and a risk of type 2 DM is presented
in Table 3.
COPD and the risk of type 2 DM Several studies
assessed the impact of COPD on the risk of new onset
type 2 DM. Rana et al. analyzed data from the Nurses’
Health Study from 1988–1996 which enrolled 103,614
females [133]. Study participants were followed for eight
years, and COPD was found to have a multivariate RR of
1.8 (95% CI 1.1-2.8) for new onset type 2 DM. It is vital
to note that the diagnosis of BA was not associated with
an increased risk of type 2 DM. However, these results
should be interpreted with caution, since spirometry
data were not available and the diagnosis of pulmonary
disease was based on the patients’ questionnaires.w onset type 2 DM
tion studied Findings
men (with no self-reported DM)
ed in the final analysis mean age:
ears mean BMI: 25.6 kg/m2
Reduced FVC, FEV1 and
MMEF were associated
with greater fasting insulin
and fasting insulin resistance
after logistic regression
analysis.
on-diabetic men age at
eginning of the study:55 years
BMI: 24.4-24.7 years
nds on the pulmonary
bgroup)
15 new cases of type 2 DM
were diagnosed during the
follow up. DM and log
glucose were inversely
associated with baseline VC.
non-diabetic subjects
-1,436, 61.57%) mean age
en: 44.0-44.9 years
nds on the pulmonary
ubgroup) mean age for
en: 49.4-50.4 years
nds on the pulmonary
ubgroup) mean BMI for men:
4.9 kg/m2(depends on the
onary FVC subgroup) mean
r women: 23.2-23.9 kg/m2
nds on the pulmonary FVC
oup)
The association between
baseline FVC and IR at follow
up remained statistically
significant after adjustment
for gender, age at screening,
follow up time, smoking/
tobacco consumption,
BMI and waist to hip ratio,
physical activity and baseline
log glucose
men non-diabetic at
ine mean age: 41.4 years
baseline BMI: 24.4 kg/m2
tients without type 2
t follow up and 26.7 kg/m2
tients with type 2 DM at
up
207 patients developed type 2 DM
with the incidence of 2.2%.
FEV1 and FVC were negatively
associated with type 2 DM.
In patients with BMI<25 kg/m2
the lowest quartile of FVC and
FEV1 had OR of 2.15
(95% CI 1.02-4.57) and
2.19 (95% CI 1.09-4.42) for
incident type 2 DM.
(100% men) mean age:
ears mean BMI: 23.3 kg/m2
Compared with the highest
FEV1 quartile, lower quartiles
were associated with
1.79-1.86 greater risk for
the new onset type 2 DM
(95% CI, 1.10-2.91).
ory Volume in 1 second; FVC: Forced Vital Capacity; HR: Hazard Ratio; MMEF:
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Study in which 38,570 women without DM were en-
rolled [134]. As in the previous study, the diagnosis of
pulmonary disease was assessed by the presence of
self-reported disease. The study participants were fol-
lowed for a median of 12.2 years. Women who had
reported physician diagnosed COPD had a multivariate
RR of 1.38 (95% CI 1.14-1.67) for new onset type 2
DM. In contrast to the previous study, these investigators
found that BA was associated with an increased risk of
type 2 DM with a RR of 1.37 (95% CI 1.2-1.57). Adapted
data from the references 132 and 133 are presented in
Figure 2.
Feary et al. analyzed the primary care records of
1,204,100 individuals aged over 35 years from 311 pri-
mary care practices in the United Kingdom [3]. They
showed an OR of 2.04 (95% CI 1.97-2.12) for the devel-
opment of new onset type 2 DM associated with phys-
ician diagnosed COPD.
Bolton et al. recruited 56 non-hypoxemic COPD
patients and 29 healthy controls to study the potential
association between inflammation and IR [135]. Patients
with COPD had higher insulin levels, which were related
to inflammatory markers such as CRP, IL-6 and soluble
receptors for TNF-α. Indeed, the COPD related inflam-
matory state may underlie the pathogenesis of an
increased risk of type 2 DM in these patients.
In contrast, Bayliss et al. failed to observe any effect of
COPD exacerbation on worsened long term glycemic
control in patients with type 2 DM [136]. However, as
was acknowledged by these researchers, the studies
using community electronic records are subject to some
limitations such as recall and selection bias; thus, the
results should be interpreted with caution.
Based on the current evidence, COPD should be
approached as a risk factor for the new onset type 2
DM. This risk is based on myriad of pathological path-






















Figure 2 COPD and the risk of type 2 DM (adapted from
references) [133,134].key studies on COPD and a risk of type 2 DM is pre-
sented in Table 4.
Treatment of COPD and the risk of hyperglycemia
Patients with COPD are often treated with corticoster-
oids, either inhaled (typically stable COPD) or systemic
(typically COPD exacerbation) [1]. Corticosteroid therapy
is associated with a decreased rate of FEV1 and pulmon-
ary function decline and fewer disease exacerbations.
However, it is well known that systemic corticosteroid
therapy is associated with multiple undesired effects,
including the development of dysglycemia and overt DM
[137]. Niewoehner et al. showed that systemic glucocorti-
costeroid therapy was significantly associated with the
development of medically relevant hyperglycemia in 271
patients with COPD exacerbation [138]. Burt et al.
showed that patients with COPD treated with systemic
corticosteroids had a circadian rise of glucose predomin-
antly in the afternoon and evening [139].
Despite being useful in the management of COPD
exacerbation, long term systemic corticosteroid therapy
is associated with the development of respiratory muscle
damage with resultant decreases in both inspiratory and
expiratory muscle strengths [140,141]. Detrimental
effects of systemic corticosteroids on respiratory per-
formance have been confirmed in patients with BA [142]
and in patients with normal baseline pulmonary func-
tion [143].
In contrast to systemic corticosteroids, inhaled corti-
costeroids have much more favorable side effect profile,
which is explained by the route of administration and a
lower corticosteroid dose being administered [144]. A re-
cently published pooled analysis of 34 studies using
inhaled steroids in patients with BA or COPD failed to
show any association with new onset type 2 DM or
hyperglycemia [145]. However, higher doses of inhaled
corticosteroids were associated with higher glucose levels
in treated patients in one published study [146].
Thus, it is critically relevant to address the risk of new
onset type 2 DM in patients with COPD being treated
with high doses of inhaled corticosteroids due to a
greater prevalence of other risk factors for DM in this
population.
The impact of DM/Mets on the lung
Effects of DM on the pulmonary vasculature and diffusing
capacity
DM is directly implicated in the development of vascular
damage to both large and small arteries or macroangiopa-
thy and microangiopathy respectively [147,148]. There-
fore, it is plausible that long standing DM detrimentally
affects the alveolar capillary bed. Key studies in this area
will be briefly reviewed.
Table 4 Key studies assessing the risk of IR/new onset type 2 DM and control of DM in patients with COPD
First author and year Country Study design Population studied Findings
Feary et al. [3]; 2010 UK Cross-sectional study
using computerized
records from 311 primary
care practices
n: 1,204,100 (Men-618,090 subjects-51.3%)
age: 35–44 years-327,800 subjects (27.2%),
45–54 years-274,375 subjects
(22.8%), 55–64 years-254,472 subjects
(21.1%), 65–74 years-177,102 subjects
(14.7%) and ≥75 years- 170,361 subjects (14.2%)
COPD had OR of 2.04
(95% CI 1.97-2.12) for the
development of new onset
type 2 DM.
Song et al. [134]; 2010 USA Prospective cohort
study with a median
follow up of 12.2 years
n:38,570 non-diabetic women mean
age-:57.8 years(for patients with physician
diagnosed COPD) mean BMI: 26.1 kg/m2
(for patients with physician diagnosed
COPD)
COPD had a multivariate
adjuster RR of 1.38
(95% CI 1.14–1.67) for
a new onset type 2 DM.
Data on BMI not provided
Bolton et al. [135]; 2007 UK Cross-sectional study n: 56 patients (30 men) with non-hypoxemic
COPD and 29 healthy subjects (15 men)
mean age: 66.7 years for COPD patients
and 62.9 years for healthy controls mean
BMI: 25.7 kg/m2 for COPD patients and
26.5 kg/m2 for healthy subjects
Patients with COPD had greater
levels of CRP, IL-6 and
TNF-α sr I and sr II.
IR assessed by HOMA was 1.68
in COPD patients vs. 1.13 in
healthy subjects.
Log10 IL-6 and BMI were found
to be predictive for IR in
stepwise regression analysis




2,332 develop chronic pulmonary disease
exacerbation (women-1,244, 53.34%),
582 (women-318, 54.64%) developed
cancer and 2,959 developed depression
(women-1,670, 56.44%) mean age at
index date: 62.04 years for depression,
63.2 years for chronic pulmonary disease
exacerbation and 65.53 years for cancer
mean BMI: 31.09 kg/m2 for cancer,
32.01 kg/m2 for depression and
32.45 kg/m2 for chronic pulmonary
disease exacerbation
The researchers did not find any
effect of chronic pulmonary
disease exacerbation,
depression and cancer on
the glycated hemoglobin.
Abbreviations: BMI: Body Mass Index; CI: Confidence Interval; COPD: Chronic Obstructive Pulmonary Disease; CRP: C-Reactive Protein; DM: Diabetes Mellitus;
HOMA: Homeostatic Model Assessment; IL-6: Interleukin-6; OR: Odds Ratio; RR: Relative Risk; sr: Soluble Receptor.
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DM with or without HF and the worsening pulmonary
diffusion capacity to carbon monoxide (DLCO) [149].
These researchers recruited 15 healthy controls and three
groups 15 patients with type 2 DM, type 2 DM+HF and
HF alone. They found that patients with both HF and type
2 DM had a lower level of DLCO, which is a known
surrogate marker for the alveolar capillary membrane
morphological and functional status. Subsequently, the
researchers tested the effects of regular insulin on DLCO.
They found that the administration of insulin improved
DLCO in patients with type 2 DM and type 2 DM+HF,
but not in patients with HF alone. The same group
tested the effects of administered regular insulin on the
alveolar gas conductance in 19 never smokers with type
2 DM [150]. They found an association between type 2
DM and decreased alveolar gas conductance. Adminis-
tered insulin improved gas conductance, which was
believed to occur through the decrease in alveolar capil-
lary membrane impedance.In fact, the observed beneficial effects of insulin on
the pulmonary variables were attractive and further
studies were carried out to explore an association with
the use of inhaled insulin [151]. However, unfortunately,
some studies pointed towards the potential adverse
effects of inhaled insulin, in terms of the occurrence of
a cough, and a potential reduction in DLCO and FEV1
[152]. Some experts doubted the usefulness of inhaled
insulin, due to an age associated decline in pulmonary
function and reserve [153] and the fact that smoking
can significantly alter the absorption of inhaled insulin
[154]. However, in contrast a recent trial did not show
any long term detrimental effects of inhaled insulin on
pulmonary variables in patients with BA [155] and a
second study did not find any harmful effects of
inhaled insulin on pulmonary function in patients with
type 2 DM [156]. Despite, these optimistic data, more
research is needed before inhaled insulin can be
recommended in diabetic patients with or without pul-
monary disease.
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and 12 healthy controls to assess the impact of type 2
DM on alveolar capillary permeability, measured using
the ratio of DLCO to alveolar ventilation (VA) [157].
The study demonstrated a statistically significant de-
crease in alveolar capillary capacity in patients with
type 2 DM compared with healthy controls. Age,
duration of type 2 DM and the presence of microalbu-
minuria were associated with the presence of alveolar
capillary exchange abnormality. It is pertinent to note
that microalbuminuria was predictive for the presence
of pulmonary capillaropathy, and it is theoretically
plausible that both diabetic related complications share
a similar pathophysiology.
Researchers from the Southwestern University, USA
enrolled 65 never smokers with type 2 DM to assess the
status of pulmonary microvascular reserve [158]. Both
non-obese (BMI<30 kg/m2) and obese (BMI≥30 kg/m2)
patients with type 2 DM had reduced levels of the mea-
sured pulmonary function variables during exercise.
However, the observed changes in obese patients were
not fully explained by the baseline lung volumes. More-
over, the presence of retinopathy, neuropathy, microal-
buminuria and control of diabetes were associated with
a reduced pulmonary microvascular reserve.
It is important to mention the findings of Minette
et al., who demonstrated that never smokers with type 1
DM had a thicker alveolar capillary membrane [159].
However, these researchers failed to find any association
between type 1 DM and worsened alveolar gas conduct-
ance. Schernthaner et al. were unable to find any adverse
impact of type 1 DM on lung function [160]. However, it
should be noted, that the cross-sectional design of the
above studies pose limitations on the study conclusion,
since the study participants could be tested at the time,
when disease was at a subclinical stage.
In contrast to these negative studies of type 1 DM and
lung diffusing capacity, the researchers from Russia
demonstrated that a long standing type 1 DM was asso-
ciated with reduced lung volumes and decreased alveolar
capillary gas exchange [161]. However, it is important to
keep in mind that patients with type 1 DM are generally
younger and may have less pulmonary damage resulting
from clinically detectable pulmonary disease compared
with type 2 DM at the time of the actual study, due to a
greater lifetime exposure to noxious stimuli and an age
related physiological decline in lung function.
Asanuma et al. compared FVC and DLCO in patients
with DM without pulmonary disease to healthy age-
matched controls [162]. They found that patients
with DM have lower DLCO and FVC in comparison
with controls. This reduction was significantly related
to the duration of DM and the presence of diabetic
retinopathy.Sandler et al. showed that patients with type 1 DM
had a lower pulmonary capillary flow with a resultant
decrease in DCLO, which was associated with the dur-
ation of DM [163]. Cooper et al. showed that older
patients (>35 years) with type 1 DM had lower DLCO
compared with controls, which might be explained by an
underlining pulmonary microvascular disease [164].
Ramirez et al. enrolled 18 patients with type 1 DM
and assigned them either to a standard insulin regimen
or to intensive treatment with measurement of glycated
hemoglobin at quarterly intervals [165]. These researchers
followed study participants for six years with measure-
ment of DLCO and FVC. Participants from the standard
treatment group had higher levels of glycated hemoglobin
and worse values of DLCO and FVC. The researchers
speculated that the treatment of DM itself may prevent
the development of pulmonary dysfunction pointing to-
ward a causative role. In a later study, the same group
supported these findings, by demonstrating diminished
DLCO and greater breathing effort in patients with type 1
DM [166].
Strojek et al. showed that patients with type 1 DM
related complications had lower levels of DLCO com-
pared with patients with type 1 DM and no complica-
tions [167]. Similar results were found by Innocenti
et al., who showed an association between urinary albu-
min excretion and diminished DLCO [168]. Schnack
et al. showed that patients with type 1 DM and microal-
buminuria had lower values of FEV1, vital capacity (VC)
and DLCO compared with patients without microalbu-
minuria and to controls [169].
Saler et al. compared DLCO between 80 healthy sub-
jects 44 patients with type 1 DM and 68 patients with
type 2 DM [170]. DLCO and the ratio of DLCO to VA
were significantly decreased in patients with both types
of DM, but not in the control group. As shown in the
above mentioned studies the urinary albumin excretion
was inversely correlated with a decline in pulmonary
diffusing capacity. It is essential to note that even chil-
dren with type 1 DM have lower DLCO, which can be
viewed as an early marker of DM related microangiopa-
thy [171].
Sinha et al. showed that patients with type 2 DM and
microangiopathy had lower DLCO in comparison with
patients with type 2 DM and no microangiopathy [172].
Boulbou et al. enrolled 16 patients with type 1 DM,
33 patients with type 2 DM and 22 healthy controls to
study the expression of adhesion molecules in all groups
[173]. Patients with both types of DM had lower levels of
DLCO corrected for alveolar ventilation and this was in-
versely related to increased expression of E-Selectin. In-
deed, based on the current data DM can be considered as
a risk factor for pulmonary capillaropathy with subsequent
alteration in DLCO.
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any association between the presence of DM and
decreased DLCO or other pulmonary function para-
meters [174]. However, some study limitations, such as a
small sample size and a relatively young age of the sub-
jects may explain these negative results.
Robust data indicate that DM leads to pulmonary
microangiopathy through the mechanisms similar to the
DM related nephropathy. This is based on the fact the
presence of DM related renal disease was significantly
associated with the presence of pulmonary capillary dys-
function. A summary of the key studies on the impact of
DM on pulmonary diffusing capacity is presented in
Table 5.
Effects of DM on the respiratory muscles and physical
endurance
DM is associated with the development of muscle dys-
function, which may not be clinically detectable, and yet
may contribute to the occurrence of diabetic complica-
tions [99,175]. Moreover, DM is independently asso-
ciated with decreased physical performance and
endurance [176]. This association can be explained by
the impact of diabetic neuropathy and the, directly detri-
mental, effects of DM on the muscle.
The diaphragm, which is a major respiratory muscle,
has the morphological structure of skeletal musculature
and can be targeted by DM related hyperglycemia [177].
Fierro et al. showed that patients with DM had
decreased phrenic nerve conduction velocity, which can
underlie a diminished respiratory performance [178].
Several other reports have highlighted the detrimental
effects of DM on the diaphragm, which are probably
mediated via phrenic neuropathy [179-181].
Polotsky et al. showed in a mouse model that the dia-
phragm glycosylation is associated with decreased hyper-
capnic ventilator response [182]. In fact, the muscular
proteins are prone to glycation, with resultant impaired
functionality, which likely explains the pathophysiology
of DM related diaphragm weakness [183]. Wanke et al.
supported the notion of impaired respiratory muscle
performance, by showing a decrease in inspiratory VC in
patients with type 1 DM [184].
Tang et al. reported a case of patient with type 2 DM
and associated phrenic neuropathy complicated by the
development of acute respiratory failure [185]. A notable
strength of their case report was that they performed a
diaphragm biopsy. In a later case report, Rison et al.
showed beneficial effects of intravenous immunoglobulin
in a patient with DM and bilateral phrenic neuropathy
[186].
Brannagan et al. reported a case of a patient with
type 1 DM and proximal diabetic neuropathy with
decreased respiratory performance [187]. Thus, it ispossible that DM may affect multiple respiratory muscles
simultaneously and contribute to impaired respiratory
performance.
Dharwadkar et al. showed that patients with type 2
DM had lower values of FEV1, FVC and maximal expira-
tory pressure which were independently related to
hyperglycemia [188]. These investigators speculated
that respiratory muscle dysfunction could underlie the
observed effects.
Several studies have pointed towards increased peripheral
airway resistance in patients with type 1 DM, which may
explain why these patients have a greater breathing effort
during exercise [189-191].
In a recently published study, Fuso et al. showed that
respiratory muscle strength in patients with type 2 DM
was significantly related to metabolic control [192].
Hyperglycemia is implicated in the dysfunction of the
diaphragm and other respiratory muscles, which lead to
decreased physical performance even in patients without
overt cardiopulmonary disease. A summary of the key
studies on the impact of DM on respiratory muscle per-
formance is presented in Table 5.
DM as a potential risk factor for accelerated decline in lung
function
As mentioned above, patients with DM have abnormal
DLCO and decreased strength of respiratory muscles.
Researchers from Japan and USA showed that patients
with DM and no pulmonary disease had lower levels of
FVC, which were related to the presence of DM related
complications [162,165]. A group from the United King-
dom demonstrated a lower total lung capacity (TLC) in
patients with type 1 DM [164]; researchers from Austria
showed decreased levels of FEV1 and VC, which were asso-
ciated with the presence of diabetic nephropathy [168].
Lange et al. analyzed data from the Copenhagen City
Heart Health Study which included 17,506 adults, 266 of
whom were diabetic [193]. They found that patients with
DM irrespective of gender had lower values of FEV1 and
FVC; however, no accelerated decline in pulmonary
function was shown during follow up compared with
subjects without DM. As discussed above, patients with
DM have impaired respiratory muscle performance and
decreased physical endurance which may underlie and
confound, the decreased pulmonary variables demon-
strated in their work. In a similar study, Walter et al.
reviewed the data from the Framingham Heart Study
[194]. They found that patients with DM had lower
levels of FEV1 and FVC even after adjustment for smok-
ing, but the diagnosis of DM was not related to COPD
independently from gender and smoking.
Lawlor et al. analyzed the data of 3,911 women en-
rolled in the British Women Heart and Health Study
[195]. These researchers showed that the presence of IR
Table 5 Some of the key studies assessing the impact of type 2 DM/MetS on the pulmonary function and COPD
First author and year Country Study design Population studied Findings
Guazzi et al. [149];
2002
Italy In hospital study assessing
the effects of regular insulin
on the alveolar-capillary
conductance.
n: 19 patients (11 men) with
type 2 DM and normal cardiac
function. mean age: 59.9 years
mean weight: 75.8 kg.
DLCO and alveolar capillary
membrane conductance were
increased by 12% and 14%
respectively by insulin therapy.
DLCO and its subcomponents
were measured.
Guazzi et al. [150];
2002
Italy Cross-sectional study. n: 30 patients with HF (19 men),
15 patients with type 2 DM
(8 men) and 15 controls (8 men).
mean age: 61.1 years for controls,
62.3 years for patients with type 2
DM, 62.8 years for patients with
type 2 DM and HF and 64.1 years
for patients with HF alone.
mean weight: 75.2 kg for patients
with HF and type 2 DM, 76.1 kg
for patients with type 2 DM,
76.7 kg for patients with HF and
77.8 kg for controls.
Patients with type 2 DM had a
lower DLCO than controls.
Regular insulin improved DLCO
in patients with type 2 DM and
type DM and HF, with no
improvement in patients with
HF alone. The improvement
in patients with type 2 DM and
HF was greater than in patients
with type 2 DM alone.
Guvener et al. [157];
2003
Turkey Cross-sectional study. n: 25 patients with type 2 DM
(9 men) and 12 healthy controls
(4 men). mean age: 56.3 years for
patients with type 2 DM and
50.1 years for controlsmean
BMI: 29.9 kg/m2 for patients with
type 2 DM and 29.5 kg/m2 for
controls.
Patients with type 2 DM had lower
ratio of DLCO to VA. In a stepwise
regression model with inclusion
of age, duration of type 2 DM
and microalbuminuria, only
microalbuminuria was found
to be independent predictor
of DLCO/VA.




capillary bed in patients
with type 2 DM.
n: 69 never smokers with type 2 DM
and no overt cardiopulmonary
disease (46% women) vs. 45 controls
(45% women). mean age: 45 years
for controls, 49 years for patients
with type 2 DM and BMI>30 kg/m2
and 45 years for patients with
type 2 DM and BMI<30 kg/m2.
mean BMI: 28.8 kg/m2 for controls,
27.4 kg/m2 and 34.4 kg/m2 for
aforementioned type 2 DM
groups respectively.
Both non-obese (BMI<30 kg/m2)
and obese (BMI≥30 kg/m2)
patients with type 2 DM had
reduced levels of the measured
pulmonary function variables
during exercise. However, the
observed changes in obese
patients were not fully explained




of diabetes were associated with
the reduced pulmonary
microvascular reserve




function at 7 years of
follow up. Aerobic exercise
capacity was measured








n: 18 subjects with type 1 DM
(11 men) and 14 controls
(10 men). mean age: 31 years for
controls and 39 for patients with
type 1 DM. mean BMI: 22 kg/m2
for controls and 24.91-25.49 kg/m2
among patients with type 1 DM.
Patients with poor glycemic
control had worse restriction
of lung volume, pulmonary
diffusing capacity and membrane
diffusing capacity. Cardiac stroke
index was reduced among
subjects with poor glycemic
control.
In the long-term analysis the rate
of FEV1 and FVC decline was
similar to those without DM.
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capillary bed in patients
with type 1 and
type 2 DM.
n: 44 subjects with type 1 DM
(29 women), 68 subjects
with type 2 DM (49 women)
and 80 controls (58 women).
mean age: 32.52 years for
patients with type 1 DM,
52.4 years for patients with
type 2 DM and 40.08 years for
controls. mean BMI: 24.4 kg/m2
for patients with type 1 DM,
27.0 kg/m2 for patients with
type 2 DM and 25.6 kg/m2
for controls.
DLCO and the ratio of DLCO to
VA were significantly decreased
in patients with both types
of DM, but not in control group.
Wanke et al. [184];
1991
Austria Cross-sectional study. n: 36 patients with type 1 DM
(31 men) and 40 controls
(33 men). mean age: 33 years
for patients with DM and
27 years for controls. mean BMI:
24.3 kg/m2 for patients with DM
and 22.3 kg/m2 for controls.
Patients with type 1 DM had
significantly lower inspiratory VC,




in patients with type 1 DM.
Walter et al. [194];
2003
USA Prospective observational
study with a follow
up>15 years using the
data of the Framingham
Heart Study.
n: 3,254 (1,547 men) with 280
subjects having type 2
DM mean age: 53.9 years
for patients without
type 2 DM and 59.6 years
for patients with type 2 DM.
mean BMI: 27.3 kg/m2 for
patients without type 2
DM and 30.67 kg/m2
for patients with type 2 DM.
Patients with type 2 DM had a
lower mean FEV1, FVC. The
FVC/FEV1 ratio was slightly
higher in patients with
type 2 DM.
Higher fasting glucose levels had
association with decreased FEV1,
FVC and FVC/FEV1 ratio
(only in current smokers).
Lawlor et al. [195];
2004
UK Cross-sectional study. N: 3,911 women
(9.8% had type 2 DM).
FEV1 and FVC were inversely
related to the HOMA score.
Age: post-menopausal women
aged 60–79 years
After adjustment for age,
anthropometric variables,
smoking, physical activity,
childhood and adult social
class and respiratory medications
the higher FEV1 and FVC were
associated with decrease in
HOMA score of 3% and
5% respectively.
Mean BMI: not provided. Patients with higher values of FEV1
and FVC had lower prevalence
of DM.
Davis et al. [196];
2004
Australia Prospective study using
the data from the
Fremantle Diabetes
Study with a mean
follow up of 7 years.
n: 125 subjects with type 2 DM.
mean age: 61.5 years mean
BMI: 29.9 kg/m2
Higher follow up fasting glucose,
greater levels of follow up
HbA1c and mean updated
HbA1c were associated with a
decrease in measured pulmonary
parameters.




Decreased FEV1 was found to be
independent predictor of
all-cause mortality.
McKeever et al. [197];
2005
UK Study analyzing the
data of the NHANES III.
n: 4,257 (1,943 men) mean
age: 37 years mean BMI:
27.0 kg/m2
Patients with higher 2 hour 75 g
glucose tolerance test had lower
levels of FEV1 and FVC.
Patients with a history of DM had
lower levels of FEV1 and patients
with poor control of DM had
lower FEV1 than patients with
controlled DM.
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Litonjua et al. [198];
2005
USA A nested case–control
study using the data of
Normative Aging Study.
n: 352 men who developed
type 2 DM and 352 controls
(all men) mean age: 43.1 years
for patients with type 2 DM
and 43.2 years for controls.
mean BMI: 26.81 kg/m2 for
patients with type 2 DM
and 25.31 kg/m2 for controls.
Patients with type 2 DM had
lower FEV1 and FVC values
(but not FEV1/FVC) many years
prior to the diagnosis of
type 2 DM.
However, there was no difference
in the rate of annual decline
of FEV1 and FVC in patients with
type 2 DM and controls.
Baker et al. [207];
2006




n: 284 subjects (167 men)
mean age: from 72.9 to
76.7 years (depends on
the glucose quartile, with
higher glucose associated
with older age) mean BMI:
not provided
The RR of death and long hospital
stay was greater in patients with
glucose from 7.0-8.9 mmol/l and
>9.0 mmol/l (RR 1.46 and 1.97
espectively), which was
independent from age, gender,
COPD severity and prior diagnosis
of DM.
The patients were divided
into 3 groups based on
the glucose quartile
(<6.0mmol/l, 6.0-6.9 mmol/
l 7.0-8.9 mmol/l and
>9 mmol/l)
Each mole increase in glucose
was associated with 15% greater
risk for adverse clinical outcome.
Higher glucose level was





UK An observation study
on the effects of
hyperglycemia




n: 88 in hospital patients
(39 men). mean age:
70 years mean BMI:
data not provided
Random blood glucose≥7.0 mmol/l
was independently associated with
an adverse NIV outcome such as
NIV failure and greater risk for
pneumonia.
Küpeli et al. [209];
2010
Turkey An observational study
assessing the correlation
between the presence
of MetS and COPD
exacerbation rate.
n: 106:29 patients with MetS
(24 men) and 77 patients
without MetS (67 men).
mean age: 64.9 years for
patients with MetS and
67.3 years for patients
without MetS.mean BMI:
30.3 kg/m2 for patients
with MetS And 27.2 kg/m2
for patients without MetS.
The mean COPD exacerbation
rate was 2.4 in MetS group
compared to 0.68 in the
control group. Mean length
of each exacerbation was
7.5 days in patients with
MetS compared to 5 days
in patients without MetS.
Serum C-reactive protein,




Abbreviations: BMI: Body Mass Index; COPD: Chronic Obstructive Pulmonary Disease; DLCO: Diffusion Capacity for Carbon Monoxide; DM: Diabetes Mellitus;
FEV1: Forced Expiratory Volume in 1 second; FVC: Forced Vital Capacity; HF: Heart Failure; HOMA: Homeostasis Model Assessment; NHANES: National Health and
Nutrition Examination Survey; MetS: Metabolic Syndrome; NIV: Non-Invasive Ventilation; PEF: Peak Expiratory Flow; RR: Relative Risk; VA: Alveolar Ventilation;
VC: Vital Capacity.
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Researchers from Australia studied the data from the
Fremantle Diabetes Study and showed that DM was
associated with lower values of FEV1, VC, FVC and peak
expiratory flow (PEF) [196]. More importantly, they
found that patients with DM had a greater rate of annual
decline in pulmonary function and, in addition, that,
DM related airflow limitation was associated with
increased mortality.
McKeever et al. analyzed data from the Third Na-
tional Health and Nutrition Examination Survey tostudy the association between glucose control and
lung function [197]. They showed that patients with
DM had lower values of FEV1 and FVC, but not a
decrease in the ratio of FEV1 to FVC. It is pertinent
to note that poor control of DM was associated with
worse pulmonary function. Litonjua et al. analyzed
data from the Normative Aging Study [198]. They
demonstrated that patients with DM had lower FEV1
and FVC values, even after adjustment for age, gender,
smoking, height and weight. However, the presence of
DM was not associated with an accelerated decline of
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out DM.
Thus, based on the above data, two major possibil-
ities exist: either that, DM independently contributes
to the pathophysiology of accelerated decline in pul-
monary function or that DM is just a marker for
decreased performance of respiratory muscles and
physical endurance. A summary of the key studies on
the impact of DM on pulmonary function is presented
in Table 5.
Impact of DM on the COPD outcomes
As mentioned above, the presence of COPD is asso-
ciated with an increased risk of comorbid diseases and
DM in particular [17]. Furthermore, comorbid diseases
including DM increase the risk of COPD exacerbation
and mortality [16].
As shown by Gan et al. and others, the risk of DM de-
velopment is associated with elevated fibrinogen and
other markers of inflammation [73,199]. In fact, this
proinflammatory state may act as an independent risk
factor and predictor for COPD exacerbations [200].
Interestingly, a lower DLCO is associated with an
increased risk of COPD exacerbation, and as discussed
above, DM can be considered as a risk factor for the de-
velopment of alveolar capilaropathy.
Dahl et al. showed that elevated CRP levels increased
the risk of COPD flares [75]. Thus, DM may aggravate
the disease course via its proinflammatory profile. It
should be emphasized that patients with frequent COPD
exacerbation have a much more rapid disease progres-
sion and related mortality, which merits particular atten-
tion to this clinical group [201].
On the other hand, all types of DM are associated with
a significantly increased risk of infections, such as pneu-
monia and bronchitis [202]. DM associated hypergly-
cemia may increase the risk of pulmonary infections by
making glucose present in the respiratory tree, which in
turn predisposes to an infectious complication [203]. On










Glucose<6.0 mmol/l Glucose 6.0-6.9
mmol/l
%
Figure 3 Serum Glucose, COPD exacerbation and in hospital mortalitglucose availability, thus causing a vicious cycle. As
shown by Phillips et al., glucose in the bronchial tree sig-
nificantly increased the risk of methicillin resistant
staphylococcus aureus (MRSA) infections in mechanic-
ally ventilated patients [204]. MRSA infections are well
known for difficulties in management and high rates of
related morbidity and mortality [205].
McAlister et al. studied the data from 2,471 patients
admitted to hospital with community acquired pneumo-
nia (CAP) and analyzed the impact of hyperglycemia on
admission to CAP outcomes [206]. These investigators
showed that admission glucose levels >11.0 mmol/l were
associated with a greater level of in hospital mortality
and morbidity. As mentioned previously, researchers
from China demonstrated a positive association between
IR, hyperglycemia and worsened outcomes during
COPD exacerbation [50].
Baker et al. analyzed the data from 284 patients
admitted to hospital with COPD exacerbation [207].
Enrolled patients were subdivided into four groups
according to their glucose levels: <6.0 mmol/l, 6.0-
6.9 mmol/l, 7.0-8.9 mmol/l and >9.0 mmol/l. This
group demonstrated that all levels of increase in glucose
were associated with increased COPD related morbidity
and mortality. Adapted data from their study is presented
in Figure 3.
Chakrabarti et al. studied 88 patients with COPD
exacerbation, which required the initiation of non-
invasive lung ventilation to assess the impact of glucose
control on disease outcomes [208]. These researchers
showed that hyperglycemia may be a clinically useful pre-
dictor of poor outcomes among patients with severe
COPD flare up requiring non-invasive ventilation.
Interesting findings were found by Küpeli et al., who
studied 106 patients with COPD, including 29 with
MetS to test the impact of MetS on COPD exacerba-
tion [209]. It was shown that patients with MetS had
a higher rate of COPD flares, and this was related to
an increase in fasting glucose, triglyceride level and
CRP. It is plausible that the low grade systemic21
31
Glucose 7.0-8.9 Glucose>9.0 mmol/l
y (adapted from reference # ) [203].
Figure 4 A simplified interrelationship between COPD and DM.
Table 6 OSA staging
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ated progression of COPD. A summary of the key
studies on the impact of DM on COPD outcomes is
presented in Table 5.
DM therapies other than insulin and pulmonary function
As discussed above insulin therapy may improve DLCO,
which acts as a surrogate marker of alveolar capillary
function. However, inhaled insulin is not generally
recommended for widespread use, because of concerns
about poor absorption and theoretically plausible side
effects.
Kim et al. retrospectively analyzed the data from 61
patients with type 2 DM with a concomitant diagnosis
of COPD [210]. These investigators showed that treat-
ment with an oral insulin sensitizer, such as metformin
or thiazolidinedione improved FVC in the recruited indi-
viduals; this observation was thought to be due to
improved respiratory muscle function. However, this
study was critically reviewed and potential limitations
were highlighted [211]. From a theoretical point of view,
antidiabetic medications may improve endothelial func-
tion [212], and may also via this mechanism improve the
functionality of pulmonary vasculature and gas diffusion.
Moreover, antidiabetic agents have been shown to be
associated with a decreased risk of lung cancer in
Taiwanese adults [213]. This is particularly relevant,
since COPD is considered to be a risk factor for lung
cancer independently from smoking [214]. Indeed, met-
formin can prevent tobacco induced lung carcinogenesis
[215] and can activate apoptosis of lung cancer cells
[216,217]. As was shown by Tan et al., metformin may
improve the efficacy of chemotherapy targeted against
non-small lung cancer in patients with type 2 DM [218].
Metformin may be beneficial in the prevention of cancer
in general, in patients with type 2 DM and may in fact
decrease mortality in patients with cancer and concomi-
tant type 2 DM [219]. However, Bodmer et al. failed to
find any effect of metformin administration on the risk
of lung cancer [220].
Furthermore, metformin has been shown to ameliorate
ventilator induced lung injury, recently demonstrated in
a rabbit model [221]. A simplified interrelationship be-
tween COPD and DM is presented in Figure 4.
OSA, overlap syndrome and the risk of type 2 DM
OSA is a common medical disorder affecting up to 24%
of the general adult population [222]. OSA is character-
ized by repetitive full and/or partial collapses of the
upper airway (UA) leading to a state of chronic intermit-
tent hypoxia. OSA is associated with low grade systemic
inflammation, oxidative stress and fundamental meta-
bolic abnormalities [223,224], including postprandial
dyslipidemia [225], an emerging risk factor for vasculardisease [226,227]. These abnormalities are believed to
underlie the increased risk for vascular [228-230] and
renal disease [231,232] seen in OSA. The disorder is
classified based on the number of apnea and/or hypop-
nea recordings per hour of sleep, which is known as
apnea hypopnea index (AHI).
The OSA staging is presented in Table 6. For a more
detailed discussion on the topic of general OSA, the
reader is referred to a well-written review article [233].
The coexistence of OSA and COPD in an individual is
called overlap syndrome. Patients with overlap syndrome
often have much more advanced cardiopulmonary dis-
ease, including pulmonary hypertension, than either dis-
ease alone. This is likely explained by far a greater
hypoxia, systemic inflammation and oxidative stress from
both diseases simultaneously. It is generally thought that
it affects approximately 1% of the adult population [234].
However, the epidemiological data are scant.
From a theoretical point, UA collapses in patients with
OSA may lead to bronchial obstruction via a reflex
mediated pathway [235]. More importantly, patients with
overlap syndrome have greater morbidity and mortality.
It was shown that continuous positive airway pressure
(CPAP) therapy has been shown to reduce the rates of
COPD exacerbations [236,237]. For a detailed discussion
on the topic of overlap syndrome, the reader is referred
to a well-written review article [234].
Figure 5 Pathophysiology of OSA mediated type 2 DM.
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overlap syndrome on glucose metabolism is scant. How-
ever, from a theoretical point of view it is highly likely
that it should lead to even greater alteration in glucose
metabolism and subsequently to type 2 DM. We will
briefly review the current evidence of OSA mediated risk
for the new onset type 2 DM.
Several mechanisms are believed to contribute to the
pathogenesis of OSA related IR: sleep fragmentation and
intermittent hypoxia [238], inflammation and oxidative
stress [239,240] and enhanced sympathetic output [224].
It is pertinent to mention that the understanding of how
OSA might lead to IR and overt type 2 DM are far from
complete. This chapter is not intended to be extensive
and the interested reader is referred to some of the well-
written review articles on this topic [78,241].
Fredheim et al. showed that OSA is much more com-
mon in patients with pre-diabetes and type 2 DM [242].
Indeed, these researchers found that OSA was present in
78% of patients with type 2 DM, compared with 67% of
patients with pre-diabetes and 38% of patients without
evidence of IR or overt type 2 DM. This was true even
after adjustment for age, gender, BMI, insulin sensitivity
and high sensitivity for CRP.
Pallayova et al. showed that patients with OSA have
lower tissue sensitivity to insulin independent of gender
and adiposity [243]. The observed association was
believed to be due to an increase in TNF-α and IL-6.
Toqeiro et al. showed that moderate and severe OSA
was independently associated with the presence of
impaired fasting glucose and markers of IR [244]. Fur-
thermore, several studies showed that OSA is independ-
ently related with an increase in glycated hemoglobin
[245,246], which is a marker of long term glucose con-
trol. Interestingly, it was recently shown that even lean
subjects with OSA have greater insulin levels as a result
of IR [247], which supports an independent role of OSA
in the development of type 2 DM.
Several prospective studies showed that OSA is an in-
dependent risk factor for the development for type 2
DM [248,249] and a recently published meta-analysis of
prospective studies confirmed this relationship [250].
Sharma et al. studied 86 patients with OSA to assess
the impact of CPAP treatment on the metabolic profile,
including the IR measurement and glycated hemoglobin
in a double-blind placebo (sham CPAP)-controlled trial
[251]. These researchers showed that CPAP therapy was
significantly associated with a statistically significant re-
duction in glycated hemoglobin levels. Weinstock et al.
showed that CPAP treatment of severe OSA is asso-
ciated with an improvement in insulin sensitivity [252].
It also has been recently shown that CPAP treatment is
independently related to an increase in peripheral insulin
sensitivity in patients with concomitant acromegaly[253]. This is particularly important since acromegaly is
associated with both type 2 DM and OS [254]. A recent
meta-analysis performed by Yang et al. supported the
beneficial effects of CPAP on the glucose metabolism
[255].
In concluding this section it is necessary to note that
emerging evidence suggests that OSA might be an inde-
pendent risk factor for the development of non-alcoholic
fatty liver disease [256], which is associated with IR and
overt type 2 DM [257], as well as vascular [258] and
renal diseases [259].
Based on the current evidence, OSA should be consid-
ered as an independent risk factor for the development
of type 2 DM, and, when coexisting with COPD, the
risks are likely to be higher. However, it is essential to
note that scientific literature is scant on the topic of
overlap syndrome and the risks of type 2 DM. A simpli-
fied sketch on how OSA may increase the risk of type 2
DM is shown in Figure 5.
Conclusion
COPD, MetS and DM are common and underdiagnosed
medical conditions. It is predicted that COPD will be
the third leading cause of death worldwide by 2020. The
burden of this disease is even greater if we consider the
significant impact of COPD on cardiovascular mortality.
COPD may be considered as a novel risk factor for
new onset type 2 DM. The pathophysiology of this is
likely to be very complex with several factors being
involved, including: inflammation and oxidative stress,
administration of glucocorticosteroids, COPD related
skeletal muscle dysfunction and abnormalities in adipo-
kine metabolism etc. However, COPD should not be
considered as a risk factor for type 1 DM, because of the
unique pathophysiology of type 1 DM and different ages
at disease presentation.
On the other hand, diabetes may act as an independ-
ent factor negatively affecting lung structure and func-
tion. Diabetes can cause muscle and neuronal damage,
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muscles. Moreover, diabetes is independently associated
with lower physical performance, which can be disabling
for patients with COPD, who already have some limita-
tion in physical performance. DM is able to detrimentally
affect alveolar capillary membrane and decrease DLCO,
similarly to other microangiopathic complications, such
as diabetic nephropathy. Furthermore, DM is associated
with the presence of glucose in airway secretions, and
this may contribute to the increased risk of pulmonary
infections seen in diabetics. MetS can increase the risk of
COPD exacerbation, and diabetes is associated with wor-
sened outcomes of COPD flares. On the top of that, co-
existent OSA may increase the risk for type 2 DM in
some individuals.
Antihyperglycemic medications may in fact improve
DLCO, as has been shown with insulin in patients with
DM. However, concerns about safety and pharmacokine-
tics preclude the recommendation for inhaled insulin to be
used at this time. On the other hand, oral antihyperglyce-
mic medications such as metformin and thiazolidinedione
may improve FVC in patients with DM. Moreover, metfor-
min has been shown to have antitumor effects and may in-
crease survival in patients with lung cancer.
Thus, it is essential to look at COPD as a potential inde-
pendent risk factor for the incidence of MetS and type 2
DM and for a complicated course of DM. Conversely, both
types of DM and MetS are associated with a worsened clin-
ical course of COPD and a greater degree of morbidity and
mortality.
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